These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 26266887

  • 1. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
    Pacilio M, Ventroni G, De Vincentis G, Cassano B, Pellegrini R, Di Castro E, Frantellizzi V, Follacchio GA, Garkavaya T, Lorenzon L, Ialongo P, Pani R, Mango L.
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
    [Abstract] [Full Text] [Related]

  • 2. A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.
    Pacilio M, Ventroni G, Cassano B, Ialongo P, Lorenzon L, Di Castro E, Recine F, Sternberg CN, Mango L.
    Ann Nucl Med; 2016 Feb; 30(2):163-8. PubMed ID: 26613714
    [Abstract] [Full Text] [Related]

  • 3. Detection and quantification of 223Ra uptake in bone metastases of patients with castration resistant prostate carcinoma, with the aim of determining the absorbed dose in the metastases.
    Mínguez P, Gómez de Iturriaga A, Fernández IL, Rodeño E.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018 Feb; 37(1):20-27. PubMed ID: 28645684
    [Abstract] [Full Text] [Related]

  • 4. The Italian multicentre dosimetric study for lesion dosimetry in 223Ra therapy of bone metastases: Calibration protocol of gamma cameras and patient eligibility criteria.
    Pacilio M, Cassano B, Chiesa C, Giancola S, Ferrari M, Pettinato C, Amato E, Fioroni F, Lorenzon L, Pellegrini R, Di Castro E, Pani R, Cremonesi M.
    Phys Med; 2016 Dec; 32(12):1731-1737. PubMed ID: 27662815
    [Abstract] [Full Text] [Related]

  • 5. The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.
    Murray I, Chittenden SJ, Denis-Bacelar AM, Hindorf C, Parker CC, Chua S, Flux GD.
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
    [Abstract] [Full Text] [Related]

  • 6. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.
    Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, Flux GD.
    J Nucl Med; 2015 Sep; 56(9):1304-9. PubMed ID: 26182965
    [Abstract] [Full Text] [Related]

  • 7. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases.
    Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD.
    Nucl Med Commun; 2012 Jul; 33(7):726-32. PubMed ID: 22513884
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.
    Yoshida K, Kaneta T, Takano S, Sugiura M, Kawano T, Hino A, Yamamoto T, Shizukuishi K, Kaneko M, Zurth C, Inoue T.
    Ann Nucl Med; 2016 Aug; 30(7):453-60. PubMed ID: 27272279
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A retrospective study on the potential of 99m Tc-HDP imaging before therapy for individualizing treatments with 223 Ra-Cl2 for metastatic castration resistant prostate cancer.
    Mínguez P, Rodeño E, Fernández I, Esteban A, Martínez-Indart L, Gómez de Iturriaga A.
    Med Phys; 2021 Mar; 48(3):1395-1403. PubMed ID: 33372286
    [Abstract] [Full Text] [Related]

  • 11. Compartmental Model for 223Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate Cancer.
    Taprogge J, Murray I, Gear J, Chittenden SJ, Parker CC, Flux GD.
    Int J Radiat Oncol Biol Phys; 2019 Nov 15; 105(4):884-892. PubMed ID: 31349058
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z, Santos-Cuevas CL, Ocampo-García BE, Ferro-Flores G, García-Becerra R, Estrada G, Gómez-Argumosa E, Izquierdo-Sánchez V.
    Nucl Med Commun; 2014 Apr 15; 35(4):423-32. PubMed ID: 24335877
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.